Introduction: B.1.351, which was found in South Africa, has three mutations (K417N, E484K, and N501Y) in the RBD.
Introduction: Finally, B.1.1.529, which was detected in Botswana on November 11, 2021 and South Africa on November 14, 2021, has 15 mutations (G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, and
Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.
Discussion: Beta variant contains nine mutations in SARS-CoV-2 spike protein: D614G, Delta242-Delta244, R246I, K417N, E484K, N501Y, and A701V.
Discussion: However, 50 mug/mL glycyrrhizic acid did not affect the binding between ACE2 and RBD with K417N-E484K-N501Y mutation.
Discussion: In conclusion, our results suggest that GB-1 could be a candidate for prophylaxis against some variants of SARS-CoV-2 infection through the inhibition of the binding between ACE2 and RBD with mutations (N501Y
SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines.
Introduction: And cilgavimab had lower activity against N501Y+D614G mutants, including B.1.429 (carrying L452R), B.1.617.2 (carrying L452R + T478K) and B.1.351 (carrying K417N + E484K + N501Y).
Introduction: However, in-vitro neutralization assays show that casirivimab alone (without imdevimab) had reduced activity against (i) K417N+ E484K substitutions found in P.1 lineage (Brazil variant), and (ii) E484Q mutation expressed in B.1.617.1/B.1.617.3 lineages (Delta/Indian variants) (FDA).
Introduction: However, it showed a significant reduction in the neutralization of B.1.351 (carrying PMID: 35273217
2022
Scientific reports
Introduction: However, neutralization of the Wuhan strain was reduced when a variant vaccine was used that contained the K417N, E484K, N501Y and D614G mutations, which agrees well with our results.
Method: Pre-fusion spike protein ectodomain DNA constructs were designed containing the following mutations compared to the Wuhan variant (Wuhan Hu-1; GenBank: MN908947.3): deletion of H69, V70 and Y144, N501Y, A570D, D614G, P681H, T716I, S982A and D1118H in Alpha; L18F, D80A, D21
A screening strategy for identifying the dominant variant of SARS-COV-2 in the fifth peak of Kurdistan- Iran population using HRM and Probe-based RT-PCR assay.
PMID: 35271889
2022
Journal of virological methods
Table: K417N
Evolutionary history of the SARS-CoV-2 Gamma variant of concern (P.1): a perfect storm.
PMID: 35266951
2022
Genetics and molecular biology
Introduction: The WHO and other reports identified several key SARS-CoV-2 S mutations in Beta (B.1.351): D80A, D215G, 241/243del, K417N, E484K, N501Y, D614G, A701V.
Discussion: VOCs Beta and Gamma share an additional RDB mutation, K417N/T , while UK researchers detected cases of Alpha lineages with the 484K allele, which also characterizes the Beta and Gamma lineages.
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Introduction: Another variant, B.1.351 (Mwenda et al.) and P.1 variant (Francisco et al.) carries 9 and 11 spike protein mutations, respectively, including 3 mutations in the receptor-binding domain (RBD), K417N/T, E484K, and N501Y.
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Result: including N501Y in both Alpha and Beta, E484K in Eta and Beta, K417N in Beta, and L452R and T478K only in Delta.
Discussion: Amino acid changes in spike proteins of variants contribute to immune evasion, and it has been suggested that N501Y is associated with increased infectivity, whereas L452R, T478K, and E484K with K417N reduce the interaction of neutralizing antibodies with RBD.
Identifying SARS-CoV-2 Variants of Concern through saliva-based RT-qPCR by targeting recurrent mutation sites.
Introduction: K417T and K417N SNPs and many substitutions at E484 also reduce viral susceptibility to neutralizing antibodies.
Result: Furthermore, of the 96 replicates that produced an inconclusive result, 74 were due to the presence of an alternate allele: 70 replicates containing E484K (B.1.351 and P.1 lineages) were inconclusive on E484Q, 4 replicates containing K417N were inconclusive for K417T (B.1.351 lineage and AY.2 sublineage) (Supplemental File 3).
Discussion: To address this, we are validating Spike SNP assays for K417N, N501Y, and G339D.
SARS_CoV_2 mutation literature information.
PMID: 
2022
Frontiers in immunology
Browser Board
Co-occurred Entities
Filtrator
ViMRT